

EXAMINER'S AMENDMENT

1. An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Kathryn Piffat on February 7, 2008.

At the end of claim 1 before the period, the following phrase was inserted: --, wherein when the quantitative ratio differs from the same quantitative ratio obtained in a sample collected from a mammal not receiving the compound or obtained from a mammalian cell or tissue culture not exposed to the compound, the compound is predicted to induce lipidosis--.

At the end of claim 6 before the period, the following phrase was inserted: --, wherein when the quantitative ratio differs from the same quantitative ratio obtained in a sample collected from a normal mammal, a diagnosis of lipidosis or a disease related thereto is made--.

2. The following is an examiner's statement of reasons for allowance: Application serial no. 10/584,366 is being allowed in view of the translation of the foreign priority document, and since none of the prior art of record teaches or fairly suggests a method for determining lipidosis in a mammal by detecting a) phenylacetylglutamine and/or phenylacetylglutamate or a metabolic intermediate of phenylacetylglutamine and/or phenylacetylglutamate in a sample obtained from the mammal, and b) hippuric acid or a metabolic intermediate of hippuric acid in the sample, and

Art Unit: 1797

predicting the presence of lipidosis in the mammal based upon the quantitative ratio of a:b, a: [a+b] or b: [a+b].

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Art Unit: 1797

3. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Maureen M. Wallenhorst whose telephone number is 571-272-1266. The examiner can normally be reached on Monday-Thursday from 6:00 AM to 4:30 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Jill Warden, can be reached on 571-272-1267. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Maureen M. Wallenhorst
Primary Examiner
Art Unit 1797

mmw

February 11, 2008

/Maureen M. Wallenhorst/

Primary Examiner, Art Unit 1797